Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Storr, Sarah J ^a   Zaitoun, Abed M ^b   Arora, Arvind ^a   Durrant, Lindy G ^a   Lobo, Dileep N ^b   Madhusudan, Srinivasan ^a   Martin, Stewart G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Ampulla; Bile duct; Calpain; Calpastatin; Cancer; Pancreas

Indexed keywords

CALPAIN 1; CALPAIN 2; CALPASTATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS CARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; VATER PAPILLA CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; AMPULLA OF VATER; BILE DUCT NEOPLASMS; CALCIUM-BINDING PROTEINS; CALPAIN; CARCINOMA; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84868552848     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-511     Document Type: Article

References (26)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
2. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362(14):1273-1281. 10.1056/NEJMoa0908721, 20375404.
3. Valsecchi ME, McDonald M, Brody JB, Hyslop T, Freydin B, Yeo CJ, Solomides C, Peiper SC, Witkiewicz AK. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer 2012, 118(14):3484-3493. 10.1002/cncr.26661, 22086503.
4. Schafer C, Seeliger H, Bader DC, Assmann G, Buchner D, Guo Y, Ziesch A, Palagyi A, Ochs S, Laubender RP, et al. Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. J Cell Mol Med 2012, 6(8):1776-1791.
5. Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer 2011, 104(9):1440-1451. 10.1038/bjc.2011.110, 3101928, 21448172.
6. Ghaneh P, Smith R, Tudor-Smith C, Raraty M, Neoptolemos JP. Neoadjuvant and adjuvant strategies for pancreatic cancer. Eur J Surg Oncol 2008, 34(3):297-305. 10.1016/j.ejso.2007.07.204, 17936564.
7. Costello E, Neoptolemos J. Enhancing the translation of cancer biomarkers. Br J Surg 2011, 98(8):1039-1040. 10.1002/bjs.7556, 21560125.
8. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev 2003, 83(3):731-801.
9. Cong J, Goll DE, Peterson AM, Kapprell HP. The role of autolysis in activity of the Ca2+-dependent proteinases (mu-calpain and m-calpain). J Biol Chem 1989, 264(17):10096-10103.
10. Imajoh S, Kawasaki H, Suzuki K. The amino-terminal hydrophobic region of the small subunit of calcium-activated neutral protease (CANP) is essential for its activation by phosphatidylinositol. J Biochem 1986, 99(4):1281-1284.
11. Glading A, Uberall F, Keyse SM, Lauffenburger DA, Wells A. Membrane proximal ERK signaling is required for M-calpain activation downstream of epidermal growth factor receptor signaling. J Biol Chem 2001, 276(26):23341-23348. 10.1074/jbc.M008847200, 11319218.
12. Hanna RA, Campbell RL, Davies PL. Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin. Nature 2008, 456(7220):409-412. 10.1038/nature07451, 19020623.
13. Moldoveanu T, Gehring K, Green DR. Concerted multi-pronged attack by calpastatin to occlude the catalytic cleft of heterodimeric calpains. Nature 2008, 456(7220):404-408. 10.1038/nature07353, 2847431, 19020622.
14. Storr SJ, Carragher NO, Frame MC, Parr T, Martin SG. The calpain system and cancer. Nat Rev Cancer 2011, 11(5):364-374. 10.1038/nrc3050, 21508973.
15. Storr SJ, Mohammed RA, Woolston CM, Green AR, Parr T, Spiteri I, Caldas C, Ball GR, Ellis IO, Martin SG. Calpastatin is associated with lymphovascular invasion in breast cancer. Breast 2011, 20(5):413-418. 10.1016/j.breast.2011.04.002, 21531560.
16. Storr SJ, Woolston CM, Barros FF, Green AR, Shehata M, Chan SY, Ellis IO, Martin SG. Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. Int J Cancer 2011, 129(7):1773-1780. 10.1002/ijc.25832, 21140455.
17. Fong PY, Fesinmeyer MD, White E, Farin FM, Srinouanprachanh S, Afsharinejad Z, Mandelson MT, Brentnall TA, Barnett MJ, Goodman GE, et al. Association of diabetes susceptibility gene calpain-10 with pancreatic cancer among smokers. J Gastrointest Cancer 2010, 41(3):203-208. 10.1007/s12029-010-9130-7, 2952047, 20178008.
18. Parnaud G, Hammar E, Rouiller DG, Bosco D. Inhibition of calpain blocks pancreatic beta-cell spreading and insulin secretion. Am J Physiol Endocrinol Metab 2005, 289(2):E313-321. 10.1152/ajpendo.00006.2005, 15784646.
19. Weber H, Jonas L, Huhns S, Schuff-Werner P. Dysregulation of the calpain-calpastatin system plays a role in the development of cerulein-induced acute pancreatitis in the rat. Am J Physiol Gastrointest Liver Physiol 2004, 286(6):G932-941. 10.1152/ajpgi.00406.2003, 15132950.
20. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2005, 2(8):416-422. 10.1038/ncponc0252, 16130938.
21. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004, 10(21):7252-7259. 10.1158/1078-0432.CCR-04-0713, 15534099.
22. Stifanese R, Averna M, De Tullio R, Pedrazzi M, Beccaria F, Salamino F, Milanese M, Bonanno G, Pontremoli S, Melloni E. Adaptive modifications in the calpain/calpastatin system in brain cells after persistent alteration in Ca2+ homeostasis. J Biol Chem 2010, 285(1):631-643. 10.1074/jbc.M109.031674, 2804211, 19880516.
23. Li S, Liang ZG, Wang GY, Yavetz B, Kim ED, Goldberg E. Molecular cloning and characterization of functional domains of a human testis-specific isoform of calpastatin. Biol Reprod 2000, 63(1):172-178. 10.1095/biolreprod63.1.172, 10859257.
24. Kumamoto T, Kleese WC, Cong JY, Goll DE, Pierce PR, Allen RE. Localization of the Ca(2+)-dependent proteinases and their inhibitor in normal, fasted, and denervated rat skeletal muscle. Anat Rec 1992, 232(1):60-77. 10.1002/ar.1092320108, 1536466.
25. Goncalves I, Nitulescu M, Saido TC, Dias N, Pedro LM JFEF, Ares MP, Porn-Ares I. Activation of calpain-1 in human carotid artery atherosclerotic lesions. BMC Cardiovasc Disord 2009, 9:26. 10.1186/1471-2261-9-26, 2706219, 19538725.
26. Neumar RW, Meng FH, Mills AM, Xu YA, Zhang C, Welsh FA, Siman R. Calpain activity in the rat brain after transient forebrain ischemia. Exp Neurol 2001, 170(1):27-35. 10.1006/exnr.2001.7708, 11421581.